The collection of studies published this year by the Beckley Foundation and our collaborators is indicative of a significant step forward for psychedelic research. Since the origins of the psychedelic renaissance in the 1990s, the Beckley Foundation has advanced the field of psychedelic science by initiating, supporting, and directing research into psychoactive substances. These drugs, despite being understudied and stigmatised, hold great promise for improving our understanding of consciousness and its neural correlates, and providing novel treatment options for neurological and psychiatric disorders.
In one of our most fascinating and important findings this year, we showed that a decrease in the connectivity of the default-mode network under LSD is associated with the experience of ‘ego-dissolution’ and ‘altered meaning’. These phenomena under psychedelics may be, at least in part, responsible for their therapeutic effect by producing a more flexible mode of thought and perception of one’s self and its relation to the world. Such a radically novel perspective could be invaluable for those struggling with rigid, destructive patterns of thought and behaviour, by which conditions such as addiction and depression are characterized. Our preliminary results provide an important foundation for future studies that will more precisely determine the neural correlates of ego-dissolution and the extent to which this aspect of the psychedelic experience results in the improvement of symptoms.
Our research has also shown that it is not just the subjective change in consciousness brought about by psychedelics that can be incredibly useful for therapy. We have also found that there are a variety of compounds contained in ayahuasca, called β-carbolines, that can strongly promote the proliferation, migration, and differentiation of stem cells in the brain into new adult neurons. Analogous to how an overactive default-mode network is a principal mechanism underlying many psychiatric illnesses, the death of brain cells is central to the pathogenesis of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, and of serious brain injuries for which current rehabilitation methods have only modest efficacy. Our research therefore provides another springboard for the development of new, cutting-edge treatment modalities for difficult-to-treat neurological disorders.
We are involved in over thirty ground-breaking scientific endeavours and have an exciting schedule for 2017. New collaborations include the first modern study to investigate the efficacy of LSD in the treatment of alcohol addiction, and an investigation into the potential of psilocybin to enhance divergent thinking – which may enable people suffering from post-traumatic stress disorder to reframe their traumatic memories. The Beckley Foundation is not only committed to furthering our understanding of the nature and extent of psychedelics’ therapeutic potential, but also to bringing them closer to the patients who need them most.
Words: Lisa Evans
Psilocybin for Depression
Type of publication